Stefano Severi
Elite in Neuroendocrine Tumor

Stefano Severi

Forli, IT 
Elite in Neuroendocrine Tumor
Forli, IT 
OverviewLocationsClinical Research

Overview

Stefano Severi practices in Forli, Italy. Mr. Severi is rated as an Elite expert by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Neuroendocrine Tumor, Long QT Syndrome 3, Prostate Cancer, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), and Cardiac Ablation.

His clinical research consists of co-authoring 129 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 37 articles and participated in 3 clinical trials in the study of Neuroendocrine Tumor.

Gender
Male

Locations

Forli, Italy
Other Locations
Cesena, Italy
Meldola, Italy
Bologna, Italy
Ozzano Monferrato, Italy
Cura, Italy
Milan, Italy
Asl, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2025
Intervention Type: Drug
Study Drugs: Lutathera, Octreotide
Study Phase: Phase 3
A Multicenter, Open-label Post Authorization Safety Study to Evaluate the Effect of LysaKare® Infusion on Serum Potassium Levels in GEP-NET Patients Eligible for Lutathera® Treatment
A Multicenter, Open-label Post Authorization Safety Study to Evaluate the Effect of LysaKare® Infusion on Serum Potassium Levels in GEP-NET Patients Eligible for Lutathera® Treatment
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: LysaKare
Study Phase: Phase 4
177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors: a Randomized Phase II Study.
177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors: a Randomized Phase II Study.
Enrollment Status: Terminated
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drugs: Capecitabine, Lu-PRRT, SS-LAR
Study Phase: Phase 2
Randomized Phase II Trial in Sstr2 Positive Tumors to Optimize the Interval Between Cycles of PRRT with 177lu-dotatate
Randomized Phase II Trial in Sstr2 Positive Tumors to Optimize the Interval Between Cycles of PRRT with 177lu-dotatate
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: PRRT
Study Phase: Phase 2
View 3 Less Clinical Trials

129 Total Publications

The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives.
The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives.
Journal: Tumori
Published: September 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Severi's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile